{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hemann EA"],"funding":["American Heart Association","Henry M. Jackson Foundation","NIDA NIH HHS","NIAID NIH HHS","American Heart Association-American Stroke Association","NHLBI NIH HHS","HHS | NIH | National Institute of Allergy and Infectious Diseases","ORFDO NIH HHS","NIH HHS"],"pagination":["1247-1256"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10149148"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["210(9)"],"pubmed_abstract":["Retinoic acid-inducible gene I (RIG-I) is essential for activating host cell innate immunity to regulate the immune response against many RNA viruses. We previously identified that a small molecule compound, KIN1148, led to the activation of IFN regulatory factor 3 (IRF3) and served to enhance protection against influenza A virus (IAV) A/California/04/2009 infection. We have now determined direct binding of KIN1148 to RIG-I to drive expression of IFN regulatory factor 3 and NF-κB target genes, including specific immunomodulatory cytokines and chemokines. Intriguingly, KIN1148 does not lead to ATPase activity or compete with ATP for binding but activates RIG-I to induce antiviral gene expression programs distinct from type I IFN treatment. When administered in combination with a vaccine aga"],"journal":["Journal of immunology (Baltimore, Md. : 1950)"],"pubmed_title":["A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity."],"pmcid":["PMC10149148"],"funding_grant_id":["75N93019C00051","U19 AI100625","W81XWH-18-2-0040","W81XWH-11-2-0174","U01 AI150747","5U01AI150747","K22AI146141","17POST33660907","75N95020D00005","75N93022D00005","HHSN27220130023C","HSSN272201400055C","75N92020D00005","R01 AI143265","HHSN272201400006C","P51 OD010425","75N99020D00005","U01AI151698","P01 AI097092","75N93019C00046","75N93021C00014","W81XWH-07-2-0067","U19AI100625 Project 3","HHSN272200900035C","U01 AI151698","HHSN272201400055C","K22 AI146141","P01AI097092","75N93023D00005"],"pubmed_authors":["Knoll ML","Gale M","Wilkins CR","Subra C","Green R","Ireton RC","Garcia-Sastre A","Trautmann L","Loo YM","Hemann EA","Thomas PG"],"additional_accession":[]},"is_claimable":false,"name":"A Small Molecule RIG-I Agonist Serves as an Adjuvant to Induce Broad Multifaceted Influenza Virus Vaccine Immunity.","description":"Retinoic acid-inducible gene I (RIG-I) is essential for activating host cell innate immunity to regulate the immune response against many RNA viruses. We previously identified that a small molecule compound, KIN1148, led to the activation of IFN regulatory factor 3 (IRF3) and served to enhance protection against influenza A virus (IAV) A/California/04/2009 infection. We have now determined direct binding of KIN1148 to RIG-I to drive expression of IFN regulatory factor 3 and NF-κB target genes, including specific immunomodulatory cytokines and chemokines. Intriguingly, KIN1148 does not lead to ATPase activity or compete with ATP for binding but activates RIG-I to induce antiviral gene expression programs distinct from type I IFN treatment. When administered in combination with a vaccine aga","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2026-05-28T21:54:19.805Z","creation":"2026-04-08T03:17:02.896Z"},"accession":"S-EPMC10149148","cross_references":{"pubmed":["36939421"],"doi":["10.4049/jimmunol.2300026"]}}